BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome; Kuvan (sapropterin dihydrochloride) for phenylketonuria; Naglazyme (galsulfase) for Mucopolysaccharidosis VI; and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A.
  • TickerBMRN
  • ISINUS09061G1013
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Valrox: NDA & MAA Submissions in Q4; We Estimate U.S./EU Launches in 2020-2021

Wedbush Research

Wedbush Morning Call - July 10 2019

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Valrox: NDA & MAA Submissions in Q4; We Estimate U.S./EU Launches in 2020-2021

Wedbush Research

Wedbush Morning Call - July 10 2019

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Valrox Late Breaker At ISTH To Be Consistent With Prior Data

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

ValuEngine Rating and Forecast Report for BMRN

BIOMARIN PHARM.INCO. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of BIOMARIN PHARM.INCO. (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date June 21, 2019, the closing price was USD 87.91 and its potential was estimated at USD 98.76.

MarketLine Department

Repligen Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Repligen Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Repligen Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantag...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch